BridgeBio Oncology Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

BBOT$2.30+12.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Balance Sheets

Conde nsed Consolidated Balance Sheets

(In thousands, except shares and per share data)

	March 31,	December 31,
	2026	2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$52,658	$373,687
Short-term marketable securities	199,617	51,773
Receivables from related parties	146	386
Prepaid expenses and other current assets	14,081	6,550
Total current assets	266,502	432,396
Long-term marketable securities	136,617	—
Property and equipment, net	938	956
Operating lease right-of-use asset	2,218	2,330
Other non-current assets	11,239	12,567
Restricted cash	132	132
Total assets	$417,646	$448,381
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity
Current liabilities:
Accounts payable	$12,090	$1,374
Accrued compensation and benefits	2,018	5,746
Accrued research and development liabilities	25,920	25,951
Accrued professional services	1,433	674
Payables to related parties	716	534
Operating lease liability, current	538	522
Other accrued liabilities	545	240
Total current liabilities	43,260	35,041
Operating lease liability, noncurrent	2,106	2,244
Total liabilities	45,366	37,285
Commitments and contingencies (Note 7)
Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of March 31, 2026 or December 31, 2025	—	—
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026; no shares issued and outstanding as of March 31, 2026; no shares authorized, issued and outstanding as of December 31, 2025	—	—
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 80,088,931 and 79,991,768 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	8	8
Additional paid-in capital	771,926	767,639
Accumulated deficit	(398,673)	(356,567)
Accumulated other comprehensive income	(981)	16
Total stockholders’ equity	372,280	411,096
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity	$417,646	$448,381

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.